Cronos GroupCRON 86 Gross Margin % is 42.36% as of Mar. 2026, which is 116% above its 10-year median of 19.61. GuruFocus rates CRON with a GF Score™ of 86/100 and a GF Value™ of $3.64 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 937 Drug Manufacturers companies, Cronos Group ranks worse than 59.87% on this metric.
The historical rank and industry rank for Cronos Group's Gross Margin % or its related term are showing as below:
CRON'
s Gross Margin % Range Over the Past 10 Years
Min: -74.09 Med: 19.61 Max: 359.64
Current: 42.74
During the past 12 years, the highestGross Margin % of Cronos Group was 359.64%. The lowest was -74.09%. And the median was 19.61%.
CRON's Gross Margin % is ranked worse than 59.87% of 937
companies
in the Drug Manufacturers industry
Industry Median: 48.46
vs CRON: 42.74
Cronos Group had a gross margin of 42.36% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Cronos Group was 0.00% per year.
Cronos Group (NAS:CRON) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cronos Group had a gross margin of 42.36% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Cronos Group Gross Margin % Related Terms
Cronos Group Gross Margin % Historical Data
* Premium members only.
The historical data trend for Cronos Group's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Cronos Group's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cronos Group (CRON) has a Gross Margin % of 42.36% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Cronos Group and its competitors. This is 116% above median its historical median of 19.61. According to the industry distribution chart, Cronos Group ranks #561 out of 937 companies in the Drug Manufacturers industry, placing it in the top 59.9%.
Is Cronos Group's Gross Margin % too high?
Cronos Group's current Gross Margin % of 42.36% is 116% above median its 10-year median of 19.61. The Drug Manufacturers industry median Gross Margin % is 48.46. Cronos Group's value of 42.36% is 12.6% below this industry median. Based on the distribution chart, Cronos Group ranks #561 out of 937 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cronos Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #561 out of 937 companies for Gross Margin %. This places Cronos Group in the lower half of its industry. The industry median Gross Margin % is 48.46. Cronos Group's value of 42.36% is 12.6% below this benchmark. While the company's 10-year median is 19.61 vs. the industry median of 48.46, Cronos Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current Gross Margin % of 42.36% is 12.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current Gross Margin % is 42.36%, which is 116% above median its own 10-year median of 19.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (CRON) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.64, compared to a current price of $2.86 — trading 21.4% below its estimated fair value. The current Gross Margin % is 42.36%, which is 116% above median its 10-year median of 19.61 and 12.6% below the Drug Manufacturers industry median of 48.46. Cronos Group's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Cronos Group (CRON), the current Gross Margin % is 42.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (CRON) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of $2.86 is trading 21.4% below its estimated GF Value™ of $3.64.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for CRON:
Gross Margin %: 42.36% (116% above median its 10-year median of 19.61)
GF Value™: $3.64 vs. price of $2.86 (21.4% below fair value)
Industry Position: 12.6% below the Drug Manufacturers median (#561 of 937)
No single metric tells the full story. See the CRON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
86GF Score
Get the complete analysis for CRON
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRON has been successfully added to your 
